reports
- Dominic Rose
- Naresh Chouhan
EU Pharma 2025 Outlook - The Correction Was Due, Tread Carefully
In the aftermath of the H224 Healthcare correction, we look forward to 2025 with a more focused stock specific approach We show sector fundamentals have remained robust despite the correction. We see 4 key themes for the Pharma sector in 2025; 1) 2025 is a very strong year for important pipeline readouts, 2) The volume impact of Medicare Part D reform will dominate the narrative in H125 & continue to be a tailwind into 2026, 3) Margin expansion should be robust at a sector level, 4) Biotech M&A...
BNP PARIBAS SA: NOTIFICATION BY THE ACPR OF THE DESIGNATION OF BNP P...
BNP PARIBAS SA: NOTIFICATION BY THE ACPR OF THE DESIGNATION OF BNP PARIBAS ON THE LIST OF G-SIBs NOTIFICATION BY THE ACPR OF THE DESIGNATION OF BNP PARIBAS ON THE LIST OF G-SIBs Press releaseParis - 27 November 2024 BNP Paribas has received the notification by the “Autorité de Contrôle Prudentiel et de Résolution” (ACPR), dated 27 November 2024, that the Group has been designated on the 2024 list of Global Systemically Important Banks (G-SIBs) in the bucket 2 corresponding to its score based on end-2023 data. Consequently, the requirement of the G-SIB buffer applicable for the group...
BNP PARIBAS SA : NOTIFICATION PAR L’ACPR DE L’APPARTENANCE DE BNP PARI...
BNP PARIBAS SA : NOTIFICATION PAR L’ACPR DE L’APPARTENANCE DE BNP PARIBAS A LA LISTE DES ETABLISSEMENTS D’IMPORTANCE SYSTEMIQUE MONDIALE (« G-SIBs ») NOTIFICATION PAR L’ACPR DE L’APPARTENANCE DE BNP PARIBAS A LA LISTE DES ETABLISSEMENTS D’IMPORTANCE SYSTEMIQUE MONDIALE (« G-SIBs ») Communiqué de presseParis - le 27 novembre 2024 BNP Paribas a reçu la notification par l’Autorité de Contrôle Prudentiel et de Résolution (ACPR), en date du 27 novembre 2024, de son appartenance à la liste 2024 des établissements d’importance systémique mondiale (EISm) dans la sous-catégorie 2 corresponda...
Philips and AWS expand strategic collaboration to advance HealthSuite ...
Philips and AWS expand strategic collaboration to advance HealthSuite cloud services and power generative AI workflows November 26, 2024 Cloud-enabled integrated diagnostics portfolio aims to unify workflows, improve access to critical insights, and drive better outcomes for patients Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the expansion of its strategic collaboration with Amazon Web Services (AWS) to offer Philips’ integrated diagnostics portfolio in the cloud, including radiology, digital pathology, cardiology [1], and ...
Philips and icometrix advance precision diagnosis in neurology with in...
Philips and icometrix advance precision diagnosis in neurology with innovative AI-based imaging solutions at #RSNA24 November 25, 2024icometrix’ FDA-cleared quantitative brain solution for neurological conditions including Alzheimer’s and multiple sclerosis is seamlessly integrated into Philips next generation BlueSeal MR scanners, and will be deployed in its comprehensive informatics platformAmsterdam, the Netherlands and Leuven, Belgium – (NYSE: PHG, AEX: PHIA), a global leader in health technology, and computer-aided diagnostics company (Leuven, Belgium) have teamed up to deploy an AI-...
Philips advances remote imaging leadership with FDA 510(k) clearance f...
Philips advances remote imaging leadership with FDA 510(k) clearance for innovative remote scanning and protocol management capabilities November 22, 2024 Vendor-agnostic, multi-modality Radiology Operations Command Center (ROCC) connects technologists, radiologists, and operations teams in real timeNew FDA 510(k) cleared remote scanning and protocol management help improve the operation of radiology workflows Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced a major step forward in making radiology expertise for diagnostic imagin...
Philips unveils next-generation BlueSeal helium-free MRI system, integ...
Philips unveils next-generation BlueSeal helium-free MRI system, integrated with AI-enabled Smart Reading at #RSNA24 Nov. 21, 2024 Industry’s first wide bore, high-performance helium-free [1] 1.5T MR features AI assistance at every step in the MRI workflow, with seamless integration of cloud-based AI image reading and reporting tools on the MR scanner Philips BlueSeal helium-free magnet combined with compact and lightweight design allows flexibility of installations in difficult and remote locations to improve wider access to advanced MRIPhilips’ award-winning [2] AI-based SmartSpeed image...
Sanofi: Information concerning the total number of voting rights and s...
Sanofi: Information concerning the total number of voting rights and shares - October 2024 Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority) Sanofia French société anonyme with a registered share capital of 2,537,214,304 €Registered office : 46, avenue de la Grande Armée - 75017 Paris - FranceRegistered at the Paris Commercial and Companie...
Sanofi: Informations relatives au nombre de droits de vote et d'action...
Sanofi: Informations relatives au nombre de droits de vote et d'actions - Octobre 2024 Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L. 233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des Marchés Financiers SanofiSociété anonyme au capital de 2 537 214 304 €Siège social : 46, avenue de la Grande Armée - 75017 Paris395 030 844 R.C.S. Paris DateNombre d’actions composant le capital Nombre réel de droits de vote (déduction faite des actions auto-détenues)Nombre théorique de droits de vote (y compris actions auto...
- Research Department
INFORME DIARIO 15 NOVIEMBRE + RDOS. ESPAÑA 3T’24. PREVIEWS (ANÁLISIS B...
COMPAÑÍAS QUE APARECEN EN EL INFORME: ESPAÑA: ACCIONA, ACCIONA ENERGÍA, CAF, CAIXABANK, COLONIAL, MERLIN. EUROPA: ASML, SANOFI. Incluido en el informe diario de hoy, y durante toda la campaña de resultados, incorporamos al final una presentación con los resultados destacados en positivo y negativo y previews de Rdos. 3T’24 que se publicarán en España y Europa en los próximos días. El BCE con el objetivo casi cumplido El Euro STOXX 50 tuvo su mejor día desde finales de septiembre mientras las ...
Press Release: Dupixent sBLA accepted for FDA review for the treatment...
Press Release: Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activityMore than 300,000 people in the US suffer from chronic spontaneous urticaria (CSU) that is inadequately controlled by antihistaminesFDA decision expected by April 18, 2025; if approved, Dupixent would be the first targeted therapy for CSU in a decade Paris and Tarrytown, NY, November 15, 202...
Communiqué de presse : La FDA a accepté l’examen de la sBLA pour le Du...
Communiqué de presse : La FDA a accepté l’examen de la sBLA pour le Dupixent dans le traitement de l’urticaire chronique spontanée La FDA a accepté l’examen de la sBLA pour le Dupixent dans le traitement de l’urticaire chronique spontanée La nouvelle demande comprend de nouvelles données pivots qui confirment que Dupixent réduit considérablement les démangeaisons et l’activité de l’urticairePlus de 300 000 personnes aux États-Unis sont atteintes d’urticaire chronique spontanée (UCS) insuffisamment contrôlée par des antihistaminiquesLa décision de la FDA attendue d’ici le 18 avril 2025 ;...
Press Release: Sarclisa recommended for EU approval by the CHMP to tre...
Press Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myeloma Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myeloma Recommendation based on IMROZ phase 3 study demonstrating Sarclisa in combination with VRd significantly improved progression-free survival, compared to standard-of-care VRd aloneIf approved, Sarclisa would be the first anti-CD38 therapy in the EU available for use in combination with VRd for adult patients with transplant-ineligible NDMM Paris, Nov...
Communiqué de presse : Sarclisa : approbation recommandée par le CHMP ...
Communiqué de presse : Sarclisa : approbation recommandée par le CHMP dans l’UE pour le traitement du myélome multiple nouvellement diagnostiqué non éligible à une greffe Sarclisa : approbation recommandée par le CHMP dans l’UE pour le traitement du myélome multiple nouvellement diagnostiqué non éligible à une greffe Recommandation fondée sur les résultats de l’étude de phase III IMROZ ayant démontré que le Sarclisa, en association avec le protocole VRd, améliore significativement la survie sans progression, comparativement au protocole VRd seul. S’il est approuvé, le Sarclisa sera le pr...
- Chaima Ferrandon
- Sven Edelfelt
FGR EIFFAGE SA
ALV ALLIANZ SE
TEP TELEPERFORMANCE SE
MRK MERCK KGAA
EOAN E.ON SE
ALO ALSTOM SA
RWE RWE AG
SAN SANOFI
NEX NEXANS SA
DTE DEUTSCHE TELEKOM AG
TIT TELECOM ITALIA S.P.A.
HLAG HAPAG-LLOYD AG
SIE SIEMENS AG
ASML ASML HOLDING NV
ALG ALLEGRO.EU SA
ENR SIEMENS ENERGY AG
DSY DASSAULT SYSTEMES SA
CVC CVC CAPITAL PARTNERS PLC
- Chaima Ferrandon
- Sven Edelfelt
FGR EIFFAGE SA
ALV ALLIANZ SE
TEP TELEPERFORMANCE SE
MRK MERCK KGAA
EOAN E.ON SE
ALO ALSTOM SA
RWE RWE AG
SAN SANOFI
NEX NEXANS SA
DTE DEUTSCHE TELEKOM AG
TIT TELECOM ITALIA S.P.A.
HLAG HAPAG-LLOYD AG
SIE SIEMENS AG
ASML ASML HOLDING NV
ALG ALLEGRO.EU SA
ENR SIEMENS ENERGY AG
DSY DASSAULT SYSTEMES SA
CVC CVC CAPITAL PARTNERS PLC
- Damien Choplain
- Martial Descoutures
Sanofi : Road show feedback: focus on growth and renewal of the pipeli...
>Growth in 2025 despite dilution due to the expected Opella transaction - Last week, we hosted a road show for Sanofi in the US with CFO, Mr François Roger. It was an opportunity recap the three topics currently driving investor interest in the stock: 1/ the sale of a controlling stake in Opella and allocation of the proceeds; 2/ pipeline progress with multiple potential blockbuster candidates; and 3/ the group’s short to med-term growth outlook. The first topic ...
- Damien Choplain
- Martial Descoutures
Sanofi : Feedback RS : croissance et renouveau du pipeline à l’honneur
>Croissance en 2025 malgré la dilution mécanique d’Opella - Nous organisions la semaine dernière le roadshow Sanofi avec son CFO, M François Roger, aux Etats-Unis. Ce rendez-vous a permis de revenir sur les trois aspects qui alimentent le marché aujourd’hui: 1/ séparation d’Opella et réallocation du capital ; 2/ évolution du pipeline et 3/ croissance court et moyen terme du groupe. Le premier point abordé concerne la vente d’Opella, Consumer business, pour un m...
Philips Spectral CT 7500 RT, world’s first spectral 4DCT respiratory-g...
Philips Spectral CT 7500 RT, world’s first spectral 4DCT respiratory-gated imaging receives FDA 510(k) clearance November 12, 2024 Designed specifically for use in radiation oncology, new Spectral CT 7500 RT enables personalized radiation therapy planning to deliver better care for more cancer patients Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced a major advance in radiation oncology with 510(k) clearance from the US Food and Drug Administration (FDA) for its new detector-based spectral computed tomography (CT) radiotherapy s...
- Cedric Rossi
- Clement Genelot
- Loic Morvan
- Philippine Adam
On the shelves now: Consumer Weekly #47
In this Consumer Weekly newsletter, we provide a brief overview of the key factors affecting our Consumer coverage, from Luxury & Consumer goods to Retail & E-commerce and Food & Ingredients. This week we look at the impact of Donald Trump's election. Happy reading!
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.